CEO Bent U. Frandsen comments:

"2023 unfolded in ways we had not anticipated, primarily due to a challenging funding environment and developments in our pipeline outside our control. However, we have commenced 2024 equipped with a clear, new strategic direction, a streamlined company, and a solid Phase III validation of our ExpreS2™ antigen production system. Our strategic goals and capital resources establish a clear framework for our continued progress. We approach the forthcoming opportunities and challenges with enthusiasm and are committed to delivering value and pioneering solutions to our stakeholders."

• Operating income amounted to 2,284 (1,583) KSEK.
• Profit/loss after financial items amounted to -19,314 (-53,287) KSEK.
• Profit/loss for the period amounted to -17,817 (-48,533) KSEK.
• Net income per share* amounted to -0.35 (-1.29) SEK.
• End of period cash balance amounted to 57,597 (110,974) KSEK.
• End of period total assets amounted to 74,255 (137,363) KSEK
• End of period equity / asset ratio amounted to 82% (75%)**

• Operating income amounted to 8,799 (6,150) KSEK.
• Profit/loss after financial items amounted to -104,555 (-126,581) KSEK.
• Profit/loss for the period amounted to -95,989 (-118,605) KSEK.
• Net income per share* amounted to -2.08 (-3.38) SEK.
• End of period cash balance amounted to 57,597 (110,974) KSEK.
• End of period total assets amounted to 74,255 (137,363) KSEK
• End of period equity / asset ratio amounted to 82% (75%)**

Figures in parenthesis are the numbers from the same period in 2022.

*The Group's net income per share: The net income for the period divided with the average number of shares for the period. For the period October to December 2023, the average number of shares amounted to 51,404,958. As of 31/12/2023, the total number of shares in ExpreS2ion Biotech Holding AB was 51,404,958.

**Equity ratio: Shareholder's equity divided by total capital.

Webcast presentation of 2023 fourth quarter and full-year results

On 8 February 2024 at 10:00 CET, ExpreS[2]ion CFO Keith Alexander will discuss the 2023 fourth quarter and full-year results and answer investors' questions. More information and registration can be found on the H.C. Andersen Capital Events website (https://www.inderes.dk/videos/expres2ion-biotechnologies-presentation-of-year-end-report-2023).

• On 23 October, the Board of Directors of ExpreS2ion Biotech Holding AB posted a notice that shareholders were thereby convened to the Extraordinary General Meeting to be held on 9 November 2023 at 10:00 CET on Mindpark, Bredgatan 11, Helsingborg, Sweden. The entrance to the meeting and registration will open at 09:30 CET.

• On 9 November 2023, ExpreS2ion held an Extraordinary General Meeting (EGM) during which a resolution was passed related to the implementation of an incentive program.

• On 16 November 2023, ExpreS2ion announced financial results for the third quarter of 2023.

• On 1 December 2023, ExpreS2ion announced the award of a Horizon Europe grant amounting to 8 million EUR, approximately 90 million SEK, to the VICI-Disease consortium, of which 53% is direct contribution for ExpreS2ion's part of the project costs. The aim is to obtain clinical proof-of-concept of a Nipah virus (NiV) vaccine candidate within four years.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB

This press release constitutes inside information that ExpreS2ion Biotech Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact persons set out below, at the time stated by the Company's news distributor, Cision, at the publication of this press release.